-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On December 23, the Guangzhou Municipal Supervision Bureau announced the third batch of typical cases of the 2021 "Iron Fist" operation.
Among them, a pharmaceutical company in Guangdong appeared on the label of its herbal tea products and some of its promotional pages claiming to prevent new coronary pneumonia and other illegal advertisements.
Content, the act was fined 300,000 yuan
.
The incident also attracted great attention in the industry
.
It is understood that since 2020, more than one pharmaceutical company has been fined for rubbing against new crown hot spots
.
For example, in August 2020, Yaben Chemical responded to investors’ questions on the interactive platform of the Shenzhen Stock Exchange about whether the company produces pharmaceutical intermediates for antiviral drugs related to the pneumonia epidemic.
Co.
, Ltd.
is a major supplier of key intermediates for the antiviral drugs atazanavir and darunavir.
It immediately received an inquiry from the China Securities Regulatory Commission and was fined 400,000 for disclosing information for falsification, and the responsible person was fined 200,000-150,000.
The fines vary
.
For another example, in June 2020, Weiming Pharmaceutical received a number of administrative supervision measures from the China Securities Regulatory Commission and imposed penalties on multiple violations of its letter and disclosure.
This included responding to investor questions on the Shenzhen Stock Exchange.
At the time of inquiry, it was stated that Beijing Kexing Biological Products Co.
, Ltd.
, the company's shareholding company, is developing a new coronary pneumonia vaccine
.
But in fact, Kexing Biological did not have an equity relationship with it.
In the end, the Securities Regulatory Commission decided to issue a warning letter to Weiming Medicine and record the relevant information in the integrity file of the securities market
.
In addition, some pharmaceutical companies have recently been punished for publishing illegal advertisements, such as exaggerating food and health products to have therapeutic effects
.
For example, in August 2021, the National Enterprise Information Information Disclosure System (Jiangsu) released a piece of information on administrative punishments for a pharmaceutical company in Nanjing.
In ", the promotion of "Xinwei'an astaxanthin yam compound tablet candy" food for infertile women can promote follicle growth and repair ovarian tissue, can delay the decline of ovarian function, and can increase FSH sensitivity, which is ovulation induction.
The effect of injection is better.
"
The "Xinwei'an Astaxanthin and Yam Compound Tablet Candy" sold by the parties are ordinary foods.
.
Due to the above illegal acts, the company was ordered to eliminate the impact within the corresponding scope and fined RMB 30,000
.
Medicines are special commodities and are closely related to the health and safety of the human body
.
Over the years, in order to protect the safety of drugs, the pharmaceutical industry has continuously tightened its supervision
.
The new "Advertising Law" has raised the upper limit of fines for "false advertisements".
The minimum fine for publishing false advertisements in violation of regulations has been increased from 1 time to 3 times advertising costs, and the punishment has been significantly increased
.
At the same time, restrictions are also imposed on the legal representatives of enterprises that publish false advertisements: the legal representatives of companies or enterprises whose business licenses have been revoked due to false advertisements or other illegal acts stipulated in this law are personally responsible for the illegal acts If the company or enterprise is liable, it shall not serve as a director, supervisor or senior manager of the company or enterprise within three years from the date when the business license of the company or enterprise is revoked
.
Generally speaking, in the era of big data and the rule of law, the illegal behavior of pharmaceutical companies will eventually bring consequences to the company, and the cost of violations is also exponentially increasing.
Only by operating in compliance can companies go further
.
At the same time, it also reminds consumers that they need to keep their eyes open to avoid falling into the "big pit" of false propaganda
.
Among them, a pharmaceutical company in Guangdong appeared on the label of its herbal tea products and some of its promotional pages claiming to prevent new coronary pneumonia and other illegal advertisements.
Content, the act was fined 300,000 yuan
.
The incident also attracted great attention in the industry
.
It is understood that since 2020, more than one pharmaceutical company has been fined for rubbing against new crown hot spots
.
For example, in August 2020, Yaben Chemical responded to investors’ questions on the interactive platform of the Shenzhen Stock Exchange about whether the company produces pharmaceutical intermediates for antiviral drugs related to the pneumonia epidemic.
Co.
, Ltd.
is a major supplier of key intermediates for the antiviral drugs atazanavir and darunavir.
It immediately received an inquiry from the China Securities Regulatory Commission and was fined 400,000 for disclosing information for falsification, and the responsible person was fined 200,000-150,000.
The fines vary
.
For another example, in June 2020, Weiming Pharmaceutical received a number of administrative supervision measures from the China Securities Regulatory Commission and imposed penalties on multiple violations of its letter and disclosure.
This included responding to investor questions on the Shenzhen Stock Exchange.
At the time of inquiry, it was stated that Beijing Kexing Biological Products Co.
, Ltd.
, the company's shareholding company, is developing a new coronary pneumonia vaccine
.
But in fact, Kexing Biological did not have an equity relationship with it.
In the end, the Securities Regulatory Commission decided to issue a warning letter to Weiming Medicine and record the relevant information in the integrity file of the securities market
.
In addition, some pharmaceutical companies have recently been punished for publishing illegal advertisements, such as exaggerating food and health products to have therapeutic effects
.
For example, in August 2021, the National Enterprise Information Information Disclosure System (Jiangsu) released a piece of information on administrative punishments for a pharmaceutical company in Nanjing.
In ", the promotion of "Xinwei'an astaxanthin yam compound tablet candy" food for infertile women can promote follicle growth and repair ovarian tissue, can delay the decline of ovarian function, and can increase FSH sensitivity, which is ovulation induction.
The effect of injection is better.
"
The "Xinwei'an Astaxanthin and Yam Compound Tablet Candy" sold by the parties are ordinary foods.
.
Due to the above illegal acts, the company was ordered to eliminate the impact within the corresponding scope and fined RMB 30,000
.
Medicines are special commodities and are closely related to the health and safety of the human body
.
Over the years, in order to protect the safety of drugs, the pharmaceutical industry has continuously tightened its supervision
.
The new "Advertising Law" has raised the upper limit of fines for "false advertisements".
The minimum fine for publishing false advertisements in violation of regulations has been increased from 1 time to 3 times advertising costs, and the punishment has been significantly increased
.
At the same time, restrictions are also imposed on the legal representatives of enterprises that publish false advertisements: the legal representatives of companies or enterprises whose business licenses have been revoked due to false advertisements or other illegal acts stipulated in this law are personally responsible for the illegal acts If the company or enterprise is liable, it shall not serve as a director, supervisor or senior manager of the company or enterprise within three years from the date when the business license of the company or enterprise is revoked
.
Generally speaking, in the era of big data and the rule of law, the illegal behavior of pharmaceutical companies will eventually bring consequences to the company, and the cost of violations is also exponentially increasing.
Only by operating in compliance can companies go further
.
At the same time, it also reminds consumers that they need to keep their eyes open to avoid falling into the "big pit" of false propaganda
.
